High Tide Announces Preliminary Q3 2025 Guidance

Core Insights - The company anticipates record revenue and adjusted EBITDA growth for Q3 2025, exceeding analyst forecasts, driven by a projected 7.4% increase in same-store sales, the fastest growth rate in two years [1][3][12] Financial Guidance - Revenue is expected to be between CAD 147.0 million and CAD 150.0 million, reflecting a quarter-over-quarter increase of 7% to 9% and a year-over-year increase of 12% to 14% [2] - Gross margin is projected to be between CAD 38.5 million and CAD 40.0 million, with a quarter-over-quarter increase of 9% to 13% and a year-over-year increase of 9% to 13% [2] - Adjusted EBITDA is expected to range from CAD 9.6 million to CAD 10.6 million, indicating a quarter-over-quarter increase of 19% and a year-over-year increase of 0% to 10% [2] Strategic Expansion - The company is expanding its operations internationally, notably through the acquisition of a majority stake in Remexian Pharma GmbH in Germany, positioning itself as a global cannabis powerhouse [3][10] Upcoming Events - Full financial and operational results for Q3 2025 will be released on September 15, 2025, followed by a conference call on September 16, 2025 [4][5]